VRPX Stock Overview A preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. More details
Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Virpax Pharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Virpax Pharmaceuticals Historical stock prices Current Share Price US$0.42 52 Week High US$5.48 52 Week Low US$0.29 Beta 0.95 1 Month Change 26.54% 3 Month Change -15.05% 1 Year Change -87.23% 3 Year Change -98.58% 5 Year Change n/a Change since IPO -99.36%
Recent News & Updates
High number of new and inexperienced directors Jan 02 Virpax Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $6 million. Jan 01
Virpax Pharmaceuticals, Inc. Announces Resignation of Gary Herman as Member of the Board of Directors and from All Committees Dec 14
High number of new and inexperienced directors Dec 01
Virpax Pharmaceuticals Receives Letter from Nasdaq Regarding Non-Compliance with Nasdaq’s Independent Director and Audit Committee Requirements under Listing Rules 5605(b)(1) and 5605(c)(2) Nov 24
Virpax Pharmaceuticals Receives a Letter from the Nasdaq Stock Market Nov 23 See more updates
High number of new and inexperienced directors Jan 02 Virpax Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $6 million. Jan 01
Virpax Pharmaceuticals, Inc. Announces Resignation of Gary Herman as Member of the Board of Directors and from All Committees Dec 14
High number of new and inexperienced directors Dec 01
Virpax Pharmaceuticals Receives Letter from Nasdaq Regarding Non-Compliance with Nasdaq’s Independent Director and Audit Committee Requirements under Listing Rules 5605(b)(1) and 5605(c)(2) Nov 24
Virpax Pharmaceuticals Receives a Letter from the Nasdaq Stock Market Nov 23
Virpax Announces Positive Results for the Swine Model Dose Range Finding Study for Probudur Nov 22 Virpax Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $5.041561 million. Nov 16
Virpax Pharmaceuticals, Inc. Announces CEO Changes
Virpax Pharmaceuticals, Inc. Receives A Delist Determination Letter from the Listing Qualifications Department of the Nasdaq Stock Market Oct 05
High number of new and inexperienced directors Oct 03
Nasdaq Grants Extension Through September 30 to Virpax Pharmaceuticals to Regain Compliance with Nasdaq Listing Rule 5550(b)(1) Jul 31 Virpax Pharmaceuticals, Inc. has filed a Follow-on Equity Offering. Jul 30
Virpax Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Jul 24
New major risk - Revenue and earnings growth Jul 20
Less than half of directors are independent Jul 10
Virpax Pharmaceuticals, Inc. Announces the Changes to Its Board of Directors Jul 08
Virpax Pharmaceuticals Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement Jul 04
New major risk - Shareholder dilution Jun 27 Virpax Pharmaceuticals, Inc., Annual General Meeting, Jul 29, 2024 Jun 15
Virpax Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $2.25 million. May 18
Virpax Pharmaceuticals, Inc. Announces Results of Maximum Tolerated Dose Study for Probudur Apr 30 Virpax Pharmaceuticals, Inc. has filed a Follow-on Equity Offering. Apr 19
Virpax Pharmaceuticals Receives Non-Compliance Letter from Nasdaq Related to Listing Rule 5550(b)(1) Apr 04
New major risk - Financial position Mar 27
Virpax Pharmaceuticals Regains Compliance with Listing Rule 5550(a)(2) Mar 18
Price target decreased by 50% to US$2.00 Feb 22
Price target decreased by 50% to US$2.00 Feb 15
Virpax Pharmaceuticals, Inc. Announces CEO Changes Nov 19 Virpax Pharmaceuticals, Inc. Announces CEO Changes Virpax Pharmaceuticals, Inc. announced delayed 10-Q filing Nov 17
Virpax Pharmaceuticals Announces Envelta Remains on Track for Trial in Humans Following FDA Review Nov 01
Nasdaq Grants Virpax Pharmaceuticals’ Request for 180-Day Extension to Regain Compliance with the Minimum Bid Price Requirement Oct 12
Novvae Pharmaceuticals Announces Executive Appointments Oct 05
Virpax Pharmaceuticals, Inc Announces the Formation of Novvae™ Pharmaceuticals Sep 19 Virpax Pharmaceuticals, Inc. Announces Update on Litigation Sep 07
Virpax Pharmaceuticals, Inc. Files Provisional Patent Application for NSAID Formulation and Method Aug 11
New major risk - Market cap size Jul 26 Virpax Pharmaceuticals, Inc. Announces CFO Changes
New minor risk - Share price stability Jun 18
Virpax Pharmaceuticals, Inc., Annual General Meeting, Jul 24, 2023 Jun 09
Virpax Pharmaceuticals, Inc. Appoints Barbara Ruskin as Class I Director Jun 08
Virpax Pharmaceuticals, Inc. Announces Positive Preclinical Toxicology Results in Support of Molecular Envelope Technology Feb 14
Virpax Pharmaceuticals Receives A Written Notice from Nasdaq Regarding Bid Price Requirement Dec 30
Virpax Pharmaceuticals, Inc. Reports on FDA Pre-IND Response for NobrXiol™ (Formerly Vrp324) Dec 15
Virpax Pharmaceuticals GAAP EPS of -$0.50 misses by $0.06 Aug 15
Virpax Pharmaceuticals, Inc. Pursues OTC Medical Device Pathway for AnQlar Jul 06
Virpax Pharmaceuticals, Inc Will Pursue Direct to OTC Pathway for Epoladerm™ for Pain Associated with Osteoarthritis Jun 28
Virpax Pharmaceuticals, Inc., Annual General Meeting, Jul 25, 2022 Jun 16
Chairman & CEO recently bought US$102k worth of stock May 22
Virpax Pharmaceuticals, Inc. Completes Initial Preclinical Studies for VRP324 Apr 27
Virpax Pharmaceuticals, Inc. Reports Favorable Preclinical Safety Data for Envelta™ for the Treatment of Acute and Chronic Pain Feb 11
Virpax Pharmaceuticals, Inc. Successfully Completes Preclinical Dermal Safety Studies for Epoladerm Jan 19
Virpax Pharmaceuticals, Inc. Announces Clinical Trial Site in Canada for First in Human Study of Epoladerm for Pain Associated with Osteoarthritis of Knee Dec 21
Virpax Pharmaceuticals, Inc. Reports Successful Results of Toxicology and Pharmacokinetic Study for Epoladerm™ Dec 09
Chairman & CEO recently bought US$100k worth of stock Nov 27
Virpax Pharmaceuticals, Inc. (NasdaqCM:VRPX) acquired Exclusive worldwide rights of Nanomerics Ltd. Sep 21
Virpax Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $40.02 million. Sep 15
Virpax: Targeting Pain At Its Source Sep 04
Virpax Pharmaceuticals, Inc Announces That the Investigational New Drug Application Enabling Studies for Envelta Jun 22
Virpax Pharmaceuticals shares surge on Envelta IND update Jun 21
Virpax(R) Pharmaceuticals Inc., Virpax Begins Ind Enabling Studies of Envelta(Tm) Feb 24
Virpax Pharmaceuticals, Inc. has completed an IPO in the amount of $18 million. Feb 18 Shareholder Returns VRPX US Pharmaceuticals US Market 7D 2.7% -0.6% -0.2% 1Y -87.2% 3.0% 25.8%
See full shareholder returns
Return vs Market: VRPX underperformed the US Market which returned 25.8% over the past year.
Price Volatility Is VRPX's price volatile compared to industry and market? VRPX volatility VRPX Average Weekly Movement 21.7% Pharmaceuticals Industry Average Movement 10.8% Market Average Movement 6.4% 10% most volatile stocks in US Market 18.6% 10% least volatile stocks in US Market 3.1%
Stable Share Price: VRPX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: VRPX's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company’s preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain.
Show more Virpax Pharmaceuticals, Inc. Fundamentals Summary How do Virpax Pharmaceuticals's earnings and revenue compare to its market cap? VRPX fundamental statistics Market cap US$2.06m Earnings (TTM ) -US$13.24m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) VRPX income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$13.24m Earnings -US$13.24m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/05 05:54 End of Day Share Price 2025/01/03 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Virpax Pharmaceuticals, Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jason McCarthy Maxim Group Nazibur Rahman Maxim Group Ashok Kumar ThinkEquity LLC
Show 0 more analysts 
